Skip to content

Oral Direct Factor Xa Inhibitor (Rivaroxaban) in Patients With Post-thrombotic Syndrome (PTS) after Stent Implantation

Oral Direct Factor Xa Inhibitor (Rivaroxaban) in Patients With Post-thrombotic Syndrome (PTS) after Stent Implantation

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020395
Enrollment
Unknown
Registered
2018-12-28
Start date
2019-01-01
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-thrombotic Syndrome

Interventions

Group 1:warfarin

Sponsors

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Past History of objectively documented deep vein thrombosis for a minimum of 6 months; 2. Villalta score of greater than 10; 3. Patients with iliac-femoral vein stenosis or occlusion and treated with stent implantation successfully 4. Followed by VKA or rivaroxaban treatment 5. Over 18 years of age.

Exclusion criteria

Exclusion criteria: 1. Episode of objectively documented deep vein thrombosis occurred less than 6 months before recruitment; 2. Childbearing potential without proper contraceptive measures, pregnancy or breast feeding; 3. Active bleeding, recent ( 175 mmHg and a diastolic > 110 mmHg; 8. Platelet count 700,000 cells/mm3; 9. Life expectancy less than 1 year; 10. Anticipated in other clinical study; 11. In the judgment of the clinician, the subject isnt suitable for this study.

Design outcomes

Primary

MeasureTime frame
Patency;

Secondary

MeasureTime frame
Major bledding;Incidence of deep vein thrombosis.;

Countries

China

Contacts

Public ContactLu Xin-wu

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

luxinwu@aliyun.com+86 13651839016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026